

Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

NCT06590896

Status	RECRUITING
Phase	Phase 2
Sponsor	Ono Pharmaceutical Co. Ltd
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (1)

- Subjects completed Study YKP3089C035 by SK Life Science.

Exclusion (2)

- Subjects that have previously discontinued for any reason from the Core study (YKP3089C035).
- Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.

Locations (29 total)

Ehime University Hospital, Ehime, Japan
Department of Neurology and Stroke Center, Southern Tohoku Clinic., Fukushima, Japan
Hiroshima University Hospital, Hiroshima, Japan
... and 26 more locations